Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
Promoting medical technology as an industry is important for Zimmer Biomet. The organisation runs a program called “Your future in STEM” helping girls at high school children consider STEM as a career, through to career professionals in the “Women-Inspired Network” or WIN as it’s commonly referred to. In clinical professions, the Zimmer Biomet “Women in Orthopaedics” program for female surgeons, acts in an advocate and support role.
Collaboration and work mindset of one team is very important for the organisation, as well as employees having a sense of belonging and being included. So whilst, talent can be difficult to find in the current market, Zimmer Biomet staff are together taking a journey of change that’s occurring across the industry.
Upbeat Edith’s energy is refreshing! Anyone looking to enter the medical technology industry and specifically the humans resources role can make a difference to people’s lives. Her advice? Be creative, work hard and have a growth mindset.
You Might also like
-
Forum fosters dialogue in breast cancer
In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.
The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.
-
Investigating use of dietary supplements for osteoarthritis
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
-
Stronger patient involvement in new medicines
New strategic agreement between Medicines Industry and Government means stronger patient involvement in new medicines.
Medicines Australia has secured a 5-year Strategic Agreement with the Federal Government, centered on earlier patient involvement and influence in the availability of new medicines in Australia.